Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P., F.A.H.A. Professor of Medicine Division of Cardiology Head, Section of Hypertension University of Maryland School of Medicine
Date: June, 2009 Contact Information Business Address:
University of Maryland Professional Building 419 West Redwood Street, Suite 620 Baltimore, Maryland 21201 Business Phone Number: (410) 3284366 Fax Number: (410) 3285745
Education 1956
B.S.
Morgan State College Baltimore, Maryland
1960
M.D.
University of Maryland School of Medicine Baltimore, Maryland
Post Graduate Education and Training Internship
(Internal Medicine)
1960 – 1961
University of Maryland Hospital Baltimore, Maryland (Internal Medicine)
Residency 1961 – 1963 Fellowship
University of Maryland Hospital Baltimore, Maryland (Cardiology)
1963 – 1965
University of Maryland Hospital Baltimore, Maryland
Certifications 1960 1970 1976 1998
National Board of Medicine Examiners, Diplomat American Board of Internal Medicine, Qualified American Board of Internal, Subspecialty, Cardiovascular Disease, Eligible American Society of Hypertension, Specialist in Clinical Hypertension, Certified
Medical Licensures Maryland #D10152
Military Service 1961 – 1967
Lieutenant Colonel
Maryland Army National Guard Reserve Baltimore, Maryland
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 2 of 25
Employment History 19601965
House Officer University of Maryland School of Medicine Baltimore, Maryland
1965 – 1984
Private Practice (Cardiology) Baltimore metropolitan area
1984 –Present
Academic Faculty and private practice Cardiology and Hypertension University of Maryland School of Medicine and University Hospital
Professional Memberships • • • • • • • • • • • • • • • • • •
Fellow, American College of Cardiology Fellow, American College of Angiology Fellow, American College of Physicians Fellow, American Heart Association Member, American Heart Association Member, Councils of Clinical Cardiology and High Blood Pressure Research (AHA) Member, Association of Academic Minority Physicians Member, American Heart Association (national and local affiliate) Member, American Medical Association Member, National Medical Association Member, Medical and Chirurgical Faculty of Maryland Member, Baltimore City Medical Society Member, Monumental City Medical Society Member, New York Academy of Science Member, Medical Alumni Association of University of Maryland Member, (Charter) American Society of Hypertension Member, (Charter) Association of Black Cardiologist (ABC) Member, (Charter) International Society of Hypertension in Blacks, Lifetime Board Member
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 3 of 25
Honors and Awards 1975
Bronze Service Medallion, Presidential Award, American Heart Association (Central Maryland)
1975
Presidential Plaque, Central Maryland Heart Association
1976
House Resolution 15 by Delegate Webster, for Distinguished Service in Maryland
1976
Silver Distinguished Service Medallion, American Heart Association, Central Maryland Chapter
1979
Silver and Presidential Award, American Heart Association, Maryland Affiliate
1979
Award of Merit, American Heart Association
1982
Distinguished Leadership Plaque, Maryland High Blood Pressure Coordinating Council
1985
Outstanding Achievement in Health Care Award, Black Nurses Association of Baltimore
1986
Elijah Saunders Scholarship, Morgan State University (To support and encourage academic excellence in chemistry, while pursuing a career in the Health Sciences)
1987
Marcus Garvey Memorial Foundation Plaque (selection as an authority on hypertension among blacks) for Centennial Year, 1987
1988
Who’s Who Among Black Americans, Page 613
1991
“Honoree of the Year”, American Heart Association, Maryland Affiliate
1991
“Doctor of the Year”, named by the Jentry McDonald Senior Group Home, Baltimore, Maryland
1991
Selected by radio station V103 for “People Who Make a Difference” calendar
1991
Nominated for the Louis B. Russell Award, American Heart Association (highest award of the AHA, honoring African Americans)
1994
Fullwood Foundation Renaissance Award for community and professional achievements
1994
Honoree, National Kidney Foundation, selected as “Leading Authority in Hypertension”
1995
Baltimore Times, “People Who Make Things Happen”
1995
Selected as one of “Top Doctors”, Baltimore Magazine, June 1995
1996
Baltimore City Medical Society Community Service Award and Plaque
1997
Recipient of Maryland Department of Health and Mental Hygiene Plaque – “Living Legend of the Black Experience”
1996.1997
Sabbatical Leave (Birmingham, England) – Research on dietary salt, salt sensitivity and hypertension in an African Caribbean population.
1996.1998
Listed by Association of Black Cardiologist in calendars as one of fourteen Pioneering African Americans in Conquest of Heart Disease
1997
Front page article in the Baltimore Sunday Sun, Racial Gap in Sickness and in Health Under Study (research on hypertension in African Americans at University of Maryland at Baltimore) August 10, 1997 Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 4 of 25
Honors and Awards
(cont’d)
1998
Article in the Perspective section of the Baltimore Sunday Sun, written by E. Saunders, M.D., on The Value of Being a Guinea Pig (encouraging minorities to participate in clinical research.) August 17, 1997
1997
Selected as one of the Top Doctors (Hypertension), Baltimore Magazine, November 1997.
1998
Awarded, Louis B. Russell Award, American Heart Association (highest award given for contribution to cardiovascular health of African Americans), June 1998
1998
Lifetime Achievement Award, consortium for Southeastern Hypertension Control (“scientist whose work has resulted in major advances in our understanding of the cardiovascular system and high blood pressure”), October 1998
1998
Award, Founders Award by the Association of Black Cardiologists, Inc. at the 25th Anniversary Awards Ceremony, November 1998
1998
Induction, First Morgan State University Hall of Fame, November 1998
1999
NAACP Award for Community Service (Black History Month), February 1999
1999
Conferred, “Doctor of Science” degree, Morgan State University, Baltimore, Maryland May 1998
1999
Conferred, Honorary Doctor’s Degree, Medical University of South Carolina, May 21, 1999
2000
Morgan State University –Alumni Hall of Fame Award, October 13, 2000
2001
Black Enterprise Magazine – Plaque featuring a special report “The Doctors Are In”, August, 2001 Issue
2002
Association of Black Cardiologists in conjunction with the National Medical Association – honored as “Cardiologist of theYear” at the Fourth Annual Testimonial Banquet
2009
Honorary Chairman, Associated Black Charities Inc., Baltimore, Maryland
2009
“Living Legend” Honoree, Associated Black Charities Inc., Baltimore Maryland. Recognized at Annual Fundraising Gala
2009
Nominee: Herbert Nickens Award of the Association of American Medical Colleges
Volunteer Services 1965 – Present
Member, Board of Trustees, First United Church (Transformation Church, Baltimore, Maryland)
1986 – 1988
Member, Capital Campaign committee, American Heart Association, (Maryland Affiliate)
1986 1988
Member, Board of Directors, John L. Deaton Medical Center, Baltimore, Maryland
1986 –1989
Member, Data Monitoring Group for National Growth and Health Study, National Heart, Lung and Blood Institute, NIH
1989 – Present
Member, Founder, Violinist & Executive Director University of Maryland Medical Center Chamber Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 5 of 25
Players (Music Director – Candy Carson) 1989 – Present
Member, Board of Directors, (International) Heart to Heart Program, International Society of Hypertension in Blacks
Volunteer Services
(cont’d)
1990 –2003
Member, External Advisory Committee on African American Study on Kidney Disease and Hypertension, National Institute on Diabetes, Digestive and Kidney Disease, NIH
1989
Member, Nomination Committee, American Heart Association (Maryland Affiliate)
1991 – 1993
Member, Ad Hoc Review Committee of the RFA, Physical Frailty in Minority Populations, NIH
1991 –1994
Member, Committee on Health Behavior Research in Minority Populations: Access, Design, and Implementation, National Heart, Lung, and Blood Institute, and the Johns Hopkins Health Institutions
1991 –1996
Member, National Heart, Lung and Blood Advisory Council, (to the director), NIH
1993 – Present
Member, Executive Council, American Society of Hypertension
1994 2004
Chairman, Governor’s Advisory Council on High Blood Pressure and Related Cardiovascular Risk Factors, State of Maryland, Department of Health and Mental Hygiene
1998
Member/PresenterPan American Hypertension Organization and National Heart, Lung and Blood Institute Workshop on global Risks of Coronary Disease in Developing Countries, NIH, Washington, DC
1998
Member/PresenterUS and South African Workshop on Hypertension, National Heart, Lung and Blood Institute, NIH, Bethesda, MD
1998 –1999
Member, American College of Cardiology, Exhibits subcommittee (Scientific Program Committee)
2000 2005
Member, Central Scholarship Bureau (Baltimore)
2003 Present
Member, Hippodrome Foundation (Baltimore)
Other Services and Memberships 1965 Present
Numerous speeches, symposia, and continuing medical education programs (national, international and local) for medical schools, hospitals, medical societies, and local physicians groups
1971
Member, OnSite Visiting Committee, National Heart, Lung and Blood Institute, Howard University School of Medicine
1972.1989
Senior (Cardiology) Member, Veterans Administration Hypertension Detection and Treatment Program, Washington, DC.
1974.1989
Member, Technical Review Panels, National Heart, Lung and Blood Institute, Heart Section
1974.1977
Member, Program Committee, American Heart Association Member, Board of Directors/Executive Committee, American Heart Association Member, Steering Committee, Hypertension Control Program of Maryland Member, Nominating Committee, American Heart Association, (Maryland Affiliate) Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 6 of 25
1975.1977
Chairman, Working Group for Minority Involvement, American Heart Association (National) Chairman, Task Force on High Blood Pressure Training and Control, American Heart Association (Maryland Affiliate)
1975.1978
Member, Stroke Committee, American Heart Association.
Other Services and Memberships (cont’d) 1976.1985
Commissioner and Charter Member, Hypertension Commission, State of Maryland
1978.1982
Member, Clinical Applications and Prevention Advisory Committee, National Heart, Lung, and Blood Institute, NIH
1978.1995
President/Founder, Urban Cardiology Research Center, Inc., Baltimore, Maryland
1979.1981
Member, Program Coordinating Council, American Heart Association, (Maryland Affiliate) Member, Black Health Providers Task Force on Hypertension Control, National Heart, Lung, and Blood Institute
1982.1985
Member, Hypertension Subcommittee, American Heart Association Chairman, Task Force for Study of Cardiovascular Disease in Black Populations, National Heart and Blood Institute
1984.1985
Member, Consensus Panel on Cholesterol Lowering, National Institutes of Health
1985.1986
Member, Search committee for President, Community College of Baltimore
1985 – Present
Member, Editorial Board, Journal of Clinical Hypertension
1986 – 1996
Member, Editorial Advisory Board, Urban Medicine
19861996
Member, Statewide Fund Raising Committee, American Heart Association, (Maryland Affiliate)
1986
CoAuthor of the TEP Paper (Tenoretic Evaluation Program), conducted by Stewart Pharmaceuticals.
1987
Consulting Editor, Pracon, Inner City Publication
1988 – 1996
Editorial Consultant, Medicine
1990
Member, Editorial Review Board, Caduceus Medical; Patterson, New Jersey
1990 – 1996
Chief Medical Editor, National Medical Association News
1991 – Present
Member, Editorial Board, Ethnicity and Disease (official journal of the International Society on Hypertension in Blacks) Reviewer, International Society on Hypertension in Blacks (Abstracts)
1991
Editor, special issue on Hypertension, Journal of the Association for Academic Minority Physicians
1994 – 1997
Editor, The Wellness Report, published by the Federal Postal Alliance Health Benefit Plan
1994 – Present
Member, Editorial Review Board, The American Journal of Cardiology Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 7 of 25
1996 – 2003
Member, Editorial Review Board, Stroke
1998 – Present
Editorial Consultant, Cardiology Review
1998 – 2003
Reviewer – The Journal of Critical Illness
1999 2008
(National) Chairman – Coalition for the Advancement of Cardiovascular Health (COACH)
2000 Present
Reviewer – American Society of Hypertension (Abstracts)
Other Services and Memberships (cont’d) 2001 Present
Reviewer – Ethnicity and Disease (Abstracts)
2002 Present
Reviewer American College of Cardiology (Abstracts)
2002 Present
Special Delegate of the American Society of Hypertension Executive Council (ASH)
2006 – Present
Editorial Consultant, Circulation
2006 – Present
Editorial Consultant, British Medical Journal
Teaching Service Basic Sciences Lectures in Pharmacology, Physiology, and Clinical Correlation for Freshman and Sophomore Medical Students: (presented yearly since 1985; following recent examples). February 10, 1995
Conference IXDiuretics and Hypertension
February 8, 1997
Clinical Correlation on Hypertension (with Dr. Bruce Hamilton)
February 24, 1997
Lecture: Essential Hypertension
February 23, 1998
Lecture: Essential Hypertension
September 25, 2003
Sophomore Physical Diagnosis
2007 – Present
Introduction to Clinical Medicine II / Physical Diagnosis
Clinical Teaching Presentations at weekly Cardiology Rounds (once or twice annually since 1984) Presentations at Morning Report (as requested) Presentations at Medical Grand Rounds or Resident conferences (once or twice each year since 1985) Presentations at various specialty rounds and departmental rounds (as requested) Presentations at Hypertension and Vascular Biology Center Rounds (yearly or as requested)
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 8 of 25
Teach and supervise junior and senior medical students, residents, fellows, and nurse practitioner students in ambulatory block rotations as electives in Hypertension (several times per year since 1984); the following represents recent examples: 2005 (December)
Van Nguyen, M.D. ( Medical Resident) Kimberly Wallace, M.D. (Medical Resident)
2005 (October)
Rajveer Sachdev, M.D. (Family Medicine Resident) K. Pargeon, M.D. (Family Medicine Resident)
2005 (September)
Mary Parreira, (Nurse Practitioner Student) Katherine Piccoli, (Nurse Practitioner Student)
2005 (August)
Nichol Bookhammer, (Nurse Practitioner Student) Vijaya L. Guduri, M.D. (Medical Volunteer) Serena McClam, M.D. (Medical Resident)
Clinical Teaching
(cont’d)
2005 (July) 2005.2006
Mabrook Shehata, M.D. ( Medical Resident) Farhan Majeed, M.D. (Cardiology Fellow) Jay Pandhi, M.D. (Cardiology Fellow) Daniel Schwartz, M.D. (Cardiology Fellow) David Wang, M.D. (Cardiology Fellow)
2005 (May)
Joseph Oppong, M.D. (Medical Resident) D. Novacic, M.D. (Medical Resident)
2005 (March)
Mulugeta Fissha, M.D. (Medical Resident)
2005 (February)
Abena OseiWusu, M.D. (Medical Resident) Eric Neufville, (Physician Assistant Student)
2005 (January)
Shernette Lyn, M.D. (Family Medicine Resident) Tracy Lehmann, (Nurse Practitioner Student) Jennifer Raichle, (Nurse Practitioner Student)
2008 – Present
Kimberlee Adkins, M.D. (Medical Resident) Yvette Castro, M.D. (Medical Resident) Danielle Brown, M.D. (Medical Resident) Camille Menino (Nurse Practitioner Student) John Van Der Merwe (Nurse Practitioner Student) Susan Shurman (Nurse Practitioner Student) Catherine Smith, M.D. (Medical Resident) Michael Banihashemi, M.D. (Medical Resident) Tania Condarco, M.D. (Medical Resident) Tenica Watt (Nurse Practitioner Student) Regina Toal (Nurse Practitioner Student)
Professional Presentations
Numerous presentations and lectures are given throughout the country and aboard at hospitals, medical meetings and professional organizations throughout the year. Among the lectures given are the following topics: • • • •
HypertensionEpidemiology , Pathophysiology, and Treatment Hypertension in Special Populations such as AfricanAmericans, Elderly, and patients with Concomitant Diseases Hypertension and Cardiovascular Diseases in AfricanAmericans New Approaches to the treatment of Heart Failure Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 9 of 25
• • •
Grant Support 1985
Presentations on pharmacologic agents in which E.S. was principal or coprincipal investigator Update on national Guidelines for the treatment of Hypertension and other Risk Factors New Clinical Trials in Hypertension and related CV Risk Factors
- Principal Investigator Marion Laboratories, Comparison study of Diltiazem vs. Atenolol in the treatment of mild to moderate hypertension. Upjohn Company, Effects of topical Minoxidil in untreated hypertensives
1985 1986
Ayerst Laboratories, Hydrochlorothiazide dose finding study with Inderal LA
1985 1996
State Department of Health and Mental Hygiene, High Blood Pressure Program.
Grant Support
- Principal Investigator
19851987
State Department of Health and Mental Hygiene, East Baltimore HBP Control Program. L. Bone, Principal Investigator, D. Levine, CoPrincipal Investigator
19861987
Marion Laboratories, Effect of calcium supplementation in young people with mild to moderate hypertension. C. Seirfert, Principal Investigator
19871988
Abbott Laboratories, Evaluation of Terazosin and Propranolol in elderly hypertensive patients including examination of plasma lipid levels and the quality of life. Matthew Weir, M.D., CoPrincipal Investigator American Cynamid Company, Evaluation of patients with 1986 mild to moderate essential hypertension. Matthew Weir, M.D., Principal Investigator Merck, Sharpe & Dohme, Vasotec vs. HCTZ in mild essential hypertension. Matthew Weir, M.D., CoPrincipal Investigator E.R. Squibb & Sons, Capozide vs. Tenoretic: Evaluation of once daily administration in mild to moderate hypertension. Matthew Weir, M.D., CoPrincipal Investigator Marion Laboratories, Diltiazem SR and HCTZ for treatment of hypertension. Matthew Weir, M.D., CoPrincipal Investigator Dupont Critical Care, Nicardipine IV in hypertensive urgencies. Matthew Weir, M.D., CoPrincipal Investigator Pfizer Pharmaceuticals, PO Nifedipine vs. IV Labetalol in hypertensive urgencies. Matthew Weir, M.D., Co Principal Investigator
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 10 of 25
1988
Merck, Sharpe & Dohme, Lisinopril vs. Verapamil older hypertensives. Matthew Weir, M.D., Co Principal Investigator
19891990
Rorer, Lozol as addon treatment to Calan SR. Matthew Weir, M.D., CoPrincipal Investigator
1989
American Cyanamid, Bisprolol. Matthew Weir, M.D., CoPrincipal Investigator Knoll, Trandolapril. Matthew Weir, M.D., Co Principal Investigator
1990
ICA Pharmaceutical Company, Zestril. Matthew Weir, M.D., CoInvestigator
1990
Glaxo, Inc., An evaluation and comparison of Isradipine vs. Hydrochlorothiazide in the regression of left ventricular hypertrophy secondary to hypertension, Phase IV. Matthew Weir, M.D., CoInvestigator CibaGeigy, A randomized, doubleblind, placebo controlled, parallelgroup comparison of monotherapy and
Grant Support
- Principal Investigator (cont’d) combined therapy of Benazepril 20mg once daily and Amlodipine in black patients with essential hypertension. Matthew Weir, M.D., CoInvestigator
1992
Merck Research Laboratories, Efficacy and tolerability of Felodipine in hypertensive blacks. Iris Keys, M.D., CoInvestigator Bristol Myers Squibb, Doubleblind, randomized trial comparing once daily combination Captopril plus Hydrochlorothiazide vs. Nifeldipine GITS in black patients with mild to moderate essential hypertension. Iris Keys, M.D., Co Investigator
1997
CibaGeigy Pharmaceuticals (Novartis), The efficacy and safety of Lotrel in African American hypertensives. Wallace Johnson, M.D. and Matthew Weir, M.D., Co Investigators Merck & Co., A multi center, doubleblind, randomized, parallel group, placebocontrolled study to investigate the anti hypertensive efficacy and safety of Losartan in African Americans with mild to moderate hypertension (protocol 17200). Wallace Johnson, M.D. and Matthew Weir, M.D., Co Investigators Astra Merck, Efficacy of Candesartan Cilexetil in hypertensive black patients: A doubleblind, randomized, placebocontrolled, parallelgroup design study with an openlabel, long term extension (Protocol 140). Matthew Weir, M.D., CoInvestigator
19972000
Astra Merck, “The ABC of Hypertension Protocol 140” Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 11 of 25
19981999
Smith, Kline, Beecham, “Cerivastain Study” Merck, Sharp & Dohme, “Losartan in Patients with Mild to Moderate Hypertension”
1998
Smith Kline Beecham, Baycol vs. Pravachol in the treatment of patients with primary hypercholesterolemia. Wallace Johnson, M.D., Co Investigator
1999
Zeneca, “A Trial to Investigate the Comparative Efficacy & Safety of Nisoldipine and Amlodipine for the Treatment of Black Subjects with Hypertension” ParkeDavis, “Effect of Quinapril on Brachial Artery FlowMay Mediated Dilation in AfricanAmerican Patients with Documented Stage I or Stage II Essential Hypertension
19981999
Covance, “Moxonidine in Stage 1 and Stage 2” Hypertension
1998
Novartis (VALUE/405), A prospective, multi national, multi center, doubleblind, randomized, activecontrolled trial in patients with essential hypertension to compare the effect of valsartan 80 and 160mg with or without the addition of hydrochlorothiazide, once daily to that of amlodopine 5 and 10mg once daily, with or without the addition of hydrochlorothiazide, on cardiovascular morbidity and mortality.
Grant Support 1999
- Principal Investigator (cont’d) ASTRAZENECA (CESNA), Safety and Efficacy Study of Sular Versus Norvasc. Bristol Myers, Omapatrilat CardiovascularTreatment Assessment Versus Enalapril (OCTAVE). Safety and Efficacy Study of Omapatrilat Dosing with Uptitration. Wallace R. Johnson, Jr, M.D., CoInvestigator
2000 2001
Covance, A doubleblind, randomized placebo and active controlled comparison study of the antihypertensive effect and safety of Eplerenone versus placebo Losartan in Black and White hypertensive patients ParkeDavis/Pfizer (CONQUER), Effect of Quinapril on Bronchial Artery FlowMedicated Dilation in AfricanAmerican Patients With Documented Stage I or Stage II Essential Hypertension. CoInvestigator, Wallace R. Johnson, Jr., M.D., ParkeDavis/Pfizer (Accuretic), Effects of the Angiotensin Converting Enzyme Inhibitor Quinapril and Quinapril and HCTZ on the Blood Pressure of Patients with Stage I and Stage II Essential Hypertension. ALTEON, Inc., A Placebo Controlled Safety and Pharmacology Study – Act 711 – In Older Patients with Stiffened Cardiovasculature. Wallace R. Johnson, Jr., CoInvestigator.
2001
COSEHC – Cardiovascular Center of Excellence. Benchmarking and followup abstraction; Implementation of quality of care improvement activities for the treatment of hypertension and Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 12 of 25
associated cardiovascular risk factors; use of instruments provided by COSEHC such as treatment algorithms, review panels and models for research; Outreach activities in the area; CME activities.
Life Study, African American Echo SubStudy of Triple – Blind Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy (LIFE). 2001
Pfizer – (AVALON TRIAL) “A Multicenter, Randomized, DoubleBlind, PlaceboControlled and Open Label Evaluation of the Safety and Efficacy of Dual Therapy with Atorvastatin plus Amlodipine When Compared to Either Therapy Alone in the Treatment of Patients with Simultaneous” Hyperlipodemia and Hypertension Protocol Number A3841001. Abbott – (TARKA) Protocol Title: A phase III, multi center, randomized, doubleblind, placebocontrolled, parallel group factorial study of metoprolol succinate extendedrelease tablets (ToprolXL®), hydrochlorothiazide and their combination in patients with essential hypertension.
2002
2003
Novartis –(DILATE) Project title: A multicenter, doubleblind, randomized study with two parallel groups comparing the effects of 12 weeks of treatment with high dose Diovan (valsartan) [320mg] to amlodipine [10mg] on endothelial function in hypertensive subjects with the metabolic syndrome (Protocol No. CVAL489A2415) [Version 2; July 2, 2002] Biovail A Prospective, Randomized, DoubleBlind, Parallel
Grant Support
- Principal Investigator (cont’d)
Group, MultiCenter, Titration Study Comparing the Safety and Efficacy of Diltiazem Hydrochloride Extended Release Tablets (G99) Taken at Bedtime to Amlodipine Taken in the Morning in Achieving Optimal Blood Pressure Control in AfricanAmerican Patients with Stage I or Stage II Essential Hypertension PROTOCOL NUMBER: B01.CT4.019.DIL G99 World Health Organization – (Interheart) “A Global Case Control study to Identify the Risk Factors for Acute Myocardial Infarction in Different Ethnic Populations”. Astra Zeneca – (ARIES) “A 6week, Randomized, OpenLabel, Comparative Study to Evaluate the Efficacy and Safety of Rosuvastatin and Atorvastatin in the Treatment of Hypercholesterolemia in African American Subjects” (ARIES) Protocol Number:4522US/0002 Astra Zeneca Site Number: 0054 Novartis – (ADDVANCE) “A Double Blind, Randomize, Parallel Group Study Comparing the Effects of Diovan HCT® (Valsartan 160mg/HCTZ 12.5 mg) to Amlodipine 10mg in AfricanAmerican Patients with Mild to Moderate Hypertension”. CibaGeigy, A randomized, doubleblind, placebo controlled, parallelgroup comparison of monotherapy and combined therapy of Benazepril 20mg once daily and Amlodipine in black patients with essential hypertension. AstraZeneca (ATTACH) A phase III, multicenter, randomized, doubleblind, placebocontrolled, parallel group factorial study of Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 13 of 25
Metoprolol succinate extendedrelease tablets (TOPROLXL), Hydrochlorothiazide and their combination in patients with essential hypertension. Pfizer (CONQUER) “Effect of Quinapril on Brachial Artery FlowMediated Dilation in AfricanAmerican Patients with Documented Stage I or II essential hypertension 2003
Abbott (TARKA) An OpenLabel, NonPlacebo, clinical trial to evaluate the efficacy of the combination drug. TARKA in the treatment of Stage II and Stage III Hypertensives with or without Diabetes or Proteinuria BMS (AVALIDE) The Efficacy and safety of Avalide 150/12.5 mg and Avalide 300/25mg in patient with hypertension uncontrolled monotherapy
2004 2005
NIH Genetic Analysis of African American Hypertension Pfizer (CAPABLE) Caduet Clinical utility of CADUET in simultaneously Achieving Blood Pressure and Lipid Endpoints in specific patient populations GlaxoSmithKline (COREG) A randomized doubleblind, multi center study comparing the effects of administration of Modified Release COREG or placebo on blood pressure in essential hypertension patients
20052006
Mylan Bertek (NEB310) A doubleblind, placeboand active controlled, forced titration study evaluating the effects of nebivolol on blood pressure and heart rate in African American patients with hypertension
Grant Support - Co-Investigator 2005 Present
National Institutes of Health (U01 HL79151) Baltimore Partnership Program to Reduce Cardiovascular Disparities
2007 – 2009
A doubleblind, randomized, placebocontrolled study to evaluate the efficacy and safety of tak491 in black subjects with essential hypertension (TL491011)
19741979
(NHLBI), Systolic Hypertension in the elderly program Roger Sherwin, M.D., and George Entwisle, M.D.
1985
Syntex Laboratories, Inc., Evaluation of Nicardipine Hydrochloride vs. Propranolol Hydrochloride as monotherapy in patients with mild to moderate hypertension. J. Josselson, Principal Investigator
1986
Merck, Sharpe & Dohme, Vosotec therapy in mild to moderate hypertension. Marion Laboratories, Nicardipine vs. Captopril for hypertension in the elderly Marion Laboratories, Comparative study of Urapidil vs. Placebo in mild to moderate hypertension
1986 1987
Marion Laboratories, Vasotec vs. Hydrochlorothiazide: Effects of drugs on blood pressure and Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 14 of 25
serum lipids in essential hypertensives 1986 1987
Marion Laboratories, DNA makers. L. Raffel, Principal Investigator Merck, Sharpe & Dohme, Red Blood Cell (Na + K) Atpase 1987 in males with newly diagnosed and previously treated essential hypertension. R. Ringel, Principal Investigator
19871988
American Cyanamid/Lederle, A randomized, doubleblind, placebocontrolled, 42day clinical trial of Nilvadipine in patients with mild to moderate essential hypertension using the Klinge formulation. Matthew Weir, Co Investigator
19881989
E.R. Squibb & Sons, Effect of Zofenopril in hypertension. Marion Laboratories, Efficacy and safety of a Diltiazem/Captopril combination compared to each agent alone and placebo in mild to moderate hypertension. Syntex Laboratories, Comparison of Nicardipine and HCTZ in the treatment of black patients with mild to moderate essential hypertension. Marion Laboratories, Effect of antihypertensive therapy on quality of life in elderly females. Marion Laboratories, Dose evaluation of Diltiazem SR/Hydrochlorothiazide in combination vs. single agents and placebo.
Grant Support – Co-Investigator (cont’d) 1990
Smith, Kline & French Laboratories, Efficacy of Carvedilol in black hypertensives. Knoll Pharmaceuticals, Openlabel study of the longterm safety of oral Trandolapril therapy in patients with mild to moderate essential hypertension (TR30HTN) Phase III. Matthew Weir, M.D., Principal Investigator Glaxo, Inc., The impact of salt sensitivity on the effects of Isradipine on blood pressure and renal hemodynamics. Matthew Weir, Principle Investigator Roerig Division of Pfizer, Inc., A multicenter evaluation of the efficacy and side effect profile of Doxazosin vs. Enalapril as initial antihypertensive therapy in patients with mild to moderate primary hypertension. Matthew Weir, M.D., Principal Investigator
1991
Knoll Pharmaceuticals, Openlabel study of the long term safety of oral Trandolapril in combination with Verapamil (Isoptin SR) (TV31HTN). Matthew Weir, M.D., Principal Investigator Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 15 of 25
Knoll Pharmaceuticals, Doubleblind, randomized, placedocontrolled, fiveway paralleldoseranging study to evaluate the safety and efficacy of oral Trandolapril therapy (4,8,12, and 16mg/day) in mild to moderate essential hypertension (TR21AHTN). Matthew Weir, M.D., 1991
Knoll Pharmaceuticals, Evaluation of the safety and efficacy of oral Trandolapril in combination with Verapamil (Isoptin SR) in patients with severe essential hypertension. Matthew Weir, M.D., Principle Investigator
1994
ParkeDavis, AIM Project, A doubleblind, randomized, comparative study to examine the singleagent efficacy of Accupril (Quinapril), vs. placebo for the treatment of mild to moderate hypertension in black and white subjects. Matthew Weir, M.D., Principal Investigator
1995
NIH (ALLHAT) Clinical Trials Center, Antihypertensive and lipidlowering treatment to prevent heart attacks. Matthew Weir, M.D., Principal Investigator
19951996
Merck & Co., ANA756 vs. Atenolol in hypertensives. Matthew Weir, M.D., Principal Investigator Merck & Co., Losartan effectiveness and tolerability (LET). Matthew Weir, M.D., Principal Investigator Astra Merck, Candesartan Cilexetil and HCTZ in hypertension. Matthew Weir, M.D., Principal Investigator
19961997
Astra Merck, Fixed combination of Candesartan and HCTZ. Matthew Weir, M.D., Principal Investigator
19961997
Bristol Myers Squibb, Dual Metalloprotease Inhibitor. Matthew Weir, M.D., Principal Investigator Forrest Labs, Calcium Channel Blockers in reducing proteinuria. Matthew Weir, M.D., Principal Investigator
Grant Support – Co-Investigator (cont’d) 19961998
1998
2000
20072009
Merck & Co., Losartan Intervention for Endpoint Reduction (LIFE). Matthew Weir, M.D., Principal Investigator The Baltimore Alliance for the Prevention and Control of Hypertension and Diabetes. Steven J. Kittner, M.D., M.P.H., Principal Investigator National Institutes of Health, Genetic Analysis of African American Hypertensives. To test the clinical consequences of basic genetic and biophysical laboratory studies of muscle contraction. A doubleblind, randomized parallelgroup study to compare the Efficacy and safety of TAK491 with Valsartan in subjects with essential hypertension
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 16 of 25
Publications Books 1.
Saunders E, Shulman N, Hall D. High Blood Pressure in Blacks: Epidemiology, Pathophysiology and Treatment. Chicago, IL:Yearbook Medical Publishers, 1985.
2.
Saunders E, et al. "Blood Pressure: Its Control and Measurement, Practitioners Manual, Fourth Edition, Revised, May, 1985.
3.
Shulman NB, Saunders E, Hall WD. High Blood Pressure. New York, NY:Macmillan Publishing Company, 1987.
4.
Shulman NB, Saunders E, Hall WD. High Blood Pressure. New York, NY:Macmillan Publishing Company, 1997. Revised.
5.
Shulman NB, Saunders E, Hall WD. Three medical experts tell you the basic facts about high blood pressure. New York, NY:Macmillan Publishing Company, Special Sales Department, 1987. (excerpted from High Blood Pressure)
6.
Saunders E, Editor. Cardiovascular Diseases in Blacks. Philadelphia, PA: F. A. Davis Company, 1991.
7.
Saunders E, Johnson W. Contemporary Diagnosis and Management of Hypertension in African Americans. Newton, PA: Handbooks in Health Care, 2003.
8.
Saunders E, Johnson W. Contemporary Diagnosis and Management of Hypertension in African Americans, Newton, PA: Handbooks in Health Care, 2006 (Update)
9.
Saunders E, Johnson W. Contemporary Diagnosis and Management of Hypertension in African Americans, Newton, PA: Handbooks in Health Care, 2009 (Update)
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 17 of 25
Monographs 1.
Saunders, E. Tenoretic Evaluation Program: "Findings Pertaining to Black Patients", pages 3136, 1985. (Co Editors: Garret, Bruce N.; Saunders, E., Schnaper, Harold and Sullivan, Jay).
2.
Saunders E, Blaustein, Mordecai P. "The Silent Killer", University of Maryland Medical System and University of Maryland School of Medicine, Maryland Medicine, Volume 4, Number 2, pp. 35, 1985.
3.
Saunders E, Smith HT. The Hypertensive Black Patient. University of Maryland School of Medicine. Clinician, Vol 10, No 6, pp.112, 1992.
4.
Saunders E. Introduction: Hypertension in AfricanAmericans Historical Perspective, Current Concepts, Future Goals. In: Emerging Perspectives in Hypertension: Focus on the AfricanAmerican patient. Health Care Communications, Inc., Fort Lee, NJ, 1994.
5.
Saunders E, Reed JW. Emerging perspectives in hypertension: focus on the African American patient historical perspective, current concepts, future goals. Health Care Communications, Inc., Fort Lee, NJ, September 1994.
6.
Saunders E, Flack JM. A target in hypertensive disease in African American patients. Health Care Communications, Inc., Fort Lee, NJ, November 1995.
7.
Saunders E, editor, Redefining Clinical Practice Patterns for CV Risk Reduction (A CME program published under the auspices of the Coalition for the Advancement of Cardiovascular Health (COACH) April, 2002.
8.
Saunders, E. editor, Redefining Clinical Practice Patterns for CV Risk Reduction (Slide Kit on CDROM) Coalition for the Advancement of Cardiovascular Health (COACH) March, 2002.
9.
Saunders, E. editor, Establishing a pattern for prevention of CV events: Focus on RAAS manipulation (A CME program published under the auspices of the Coalition for the Advancement of Cardiovascular Health (COACH) August, 2004.
10.
Saunders, E. editor, The Challenge of Cardioprotection: Redefining RAAS Modulation (A CME program published under the auspices of the Coalition for the Advancement of Cardiovascular Health (COACH) August, 2005.
11.
Saunders, E. editor, ACE inhibition and cardiovascular protection: The PEACE conflict (A CME program published under the auspices of the Coalition for the Advancement of Cardiovascular Health (COACH) January, 2005.
12.
Saunders, E. editor, Redefining Cardioprotection: The Evolution of RAAS Modulation, 2005 COACH RAAS Core Curriculum.
13.
Saunders, E. , Dennison, Cheryl R. Managing Hypertension in Primary Care Practice: What’s New and What Needs to Change (Live Web Conference) May 12, 2005.
14.
Saunders, E. editor, Patient Care Seminar “Challenges and Opportunities in Cardiovascular Risk Reduction” COACH October, 2005.
15.
Robinson SW, Saunders E. Will Race Matter in the Era of Personalized Medicine? Cardiology Today, August 2009.
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 18 of 25
Chapters 1.
Saunders E. Textbook of Black Related Diseases, Chapter 7 (Hypertension), McGraw Hill Publishers 1975; 333356.
2.
Saunders E. Special techniques for management of hypertension in blacks, Chapter 14, "Hypertension in Blacks", Yearbook Medical Publishers 1985; 209236.
3.
Davidson P, Saunders E. Epidemiologic and clinical comparison of cardiovascular disease in blacks and whites in the USA. In: Cruickshank JK, Beevers DG, ed. Ethnic Factors in Health and Disease. Butterworth & Co., Ltd. 1989; 4847.
4.
Saunders E. Therapy of hypertension in the black patient. In: Puschett JB, Greenberg G, ed. Diuretics III., Chemistry, Pharmacology, and Clinical Applications. New York: Elsevier Science Publishing Co., Inc., 1990; 457465.
5.
Hildreth C, Saunders E. Hypertension in Blacks: Clinical Overview. Cardiovascular Diseases in Blacks, F. A. Davis, Company, Philadelphia, PA 1991; 8596.
6.
Saunders E. Hypertension in Blacks. Primary Care: Clinics in Office Practice, Philadelphia, PA, 1991;Vol 18, Number 3:607622.
7.
Hildreth C, Saunders E. Heart Disease, Stroke and Hypertension in Blacks. In Health Issues in the Black Community. San Francisco, CA, JosseyBass, Inc., 1992; 90105.
8.
Keys I, Saunders E. Therapy for the black hypertensive. In: Individualized Therapy of Hypertension. Edited by Kaplan, NM and Ram CV. New York, NY, Marcel Dekker, Inc. 1994; 8394.
9.
Satcher D, Pamies R, JonesBurton C, Saunders E, Multicultural Medicine and Health Disparities, Cardiovascular Disease, Hypertension, and Renal Disease: A Focus on African Americans, 2005
Refereed Publications Articles 1.
McCrumb Jr FR, Kress S, Saunders E, Snyder MM, Schluederberg A. Studies with live attenuated measles virus vaccine. (Clinical and immunologic responses in institutionalized children). Amer. J of Diseases of Children 1961; 101:689712.
2.
Attar S., Saunders E., McLaughlin J., Scherlis, L., RA. Prosthetic heart valve surgery evaluation of early and late complications. Annals of Thoracic Surgery 1966; 2:5263.
3.
Attar S, Saunders E, McLaughlin J, Scherlis L, Cowley RA. Prosthetic heart valve surgery in acquired valvular heart disease. American Surgeon, Jan. 1966; 33(4):294297.
4.
Saunders E, Curry C, Hinds J, Kong B, Medakovic M, Poland M, Roper K. Labetalol compared with propranolol in the treatment of black hypertensive patients. Journal of Clinical Hypertension 1987; 3:294302.
5.
Saunders E. Special management techniques for hypertension in blacks. Journal of Clinical Hypertension 1987; 3:1620.
6.
Maxwell MH, Morton H, Garrett BN, Saunders E, Schnaper H. Postmarketing survey of the effects of an Atenolol/Chlorthalidone combination in the treatment of hypertension. Clinical Therapeutics 1987; Vol. 9, No. 4 Exerpta Medical 1987; 380389.
7.
Weir M, Josselson J, Girard MJ, Warren JB, Posner JN, Lam YW, Zaske DE, Saunders E. Sustainedrelease dilitizem compared with atenolol monotherapy for mild to moderate systemic hypertension. American Journal of Cardiology, December 14, 1987; 60(17):361411. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 19 of 25
8.
Saunders E. Stepped Care and Profiled Care in the Treatment of Hypertension: Considerations for Black Americans. Am. J. Med. 9:380389, 1987.
Refereed Publications (cont’d) Articles 9.
Saunders E. Hypertension in Blacks. Med. Clin. North Am. 71:10131029, 1987.
10. Saunders E. Drug treatment considerations for the hypertensive black patient. Journal of Family Practice 1988 (June); 26(6):659664. 11. Weir M, Saunders E. Pharmacologic management of hypertension in blacks. American Journal of Cardiology, June 15, 1988; 61(16):46H52H. 12. Weir MR, Kritchen C, Urick A, Saunders E, Lavin PT. Comparison of enalipril and hydrochlorothiazide in mild hypertension and changes in plasma lipid concentrations during therapy. Clinical Therapeutics 1988; 10:712724. 13. Kaplan NM, Alderman MH, Flamebaum W, McCarron DA, Perry HM, Saunders E, Schoenberger JA. Guidelines for the treatment of hypertension.. American Journal of Hypertension 1989 (Feb); 2(2pt1):7577. 14. Wallin J.D., Fletcher E., Ram C.V., Cook M.E., Cheung D.G., MacCarthy E.P., Townsend R. Saunders E., Davis W.R., Langford H.G., et. al. Intravenous Nicardipine for the Treatment of Severe Hypertension. A DoubleBlind, PlaceboControlled Multicenter Trial. Arch. Intern. Med. 149:26622669, 1989. 15. Materson B.J., Vlachakis N.D., Glasser S.P., Lucas C. Ramanathan K.B., Ahmad S., Morledge J. H., Saunders E., Lutz L.J., Schnaper H.W., et. al. Influence of Beta 2 Agonism and Beta 1 and Beta Antagonism on Adverse Effects and Plasma Lipoproteins: Results of a Multicenter Comparison of Dilevalol and Metoprolol. J. Natl. Med. Assoc. 81:511, 1989. 16. Saunders E, Weir MR, Kong BW, et. al. A comparison of the efficacy and safety of a betablocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Archives of Internal Medicine 1990; 150:17071713. 17. Weir M.R., Vlachkis N.D., DeQuattro V., Douglas J., Svetkey L.P., Singh S., Wiedl S.C., Chen C.F., Woodward D.L., Saunders E. Evaluation of the Clinical Pharmacology of Nilvadipine in Patients with Mild to Moderate Essential Hypertension. J. Clin. Pharmacol. 30:425437, 1990. 18. Croog SH, Kong BW, Levine S, Weir MW, Baume RM, Saunders E. Hypertensive black men and women. Quality of life and effects of antihypertensive medications. Black quality of life multicenter trial group. Archives of Internal Medicine 1990; 150:17331741. 19. Weir MR, Cassidy CA, Hall PS, Lancaster A, Schubert C, Urick A, Saunders E, Kong BW, Jenkins P, Lavin PT. Efficacy and tolerability of enalapril and sustainedrelease verapamil in older patients with mild to moderate essential hypertension. Clinical Therapy 1990; 12:139148. 20. Saunders E. The Safety and Efficacy of Terazosin in the Treatment of Essential Hypertension in Blacks. Am. Heart J. 122:936942, 1991. 21. Hildreth C.J., Saunders E. Hypertension in Blacks. MD Med. J. 40:213217, 1991. 22. Hildreth C., Saunders E. Hypertension in Blacks: Clinical Review. Cardiovasc. Clin. 21:8586, 1991. 23. Saunders E. Hypertension in the Black Population: Measures for Improving the Outlook. Cardiovascular Reviews & Reports. 13:4951, 1992 24. Saunders E. Hypertension in Minorities: Blacks. Am. J. Hypertens. 8:115s119s, 1995. 25. Saunders E. Recruitment of AfricanAmerican Patients for Clinical Trials—The Allhat Challenges. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 20 of 25
Antihypertensive and LipidLowering Trial to Prevent Heart Attack. J. Natl. Med. Assoc. 87:627629, 1995. 26. Saunders E. Pharmacologic Initiatives in Black Hypertensives. PA Med. 98:3438, 1995.
Refereed Publications (cont’d) Articles 27. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin converting enzyme inhibition in black and white hypertensive patients. The trandolapril multi center study group. Hypertension, July 1995; 26(1):124130. 28. Saunders E, Neutel J. A new antihypertensive strategy for black patients: lowdose multimechanism therapy. Journal of the National Medical Association 1996; 171175. 29. Weir MR, Saunders E. Renin status does not predict the antihypertensive response to angiotensin converting enzyme inhibition in African Americans. American Journal of Hypertension 1996. 30. Weir MR, Sugimoto D, Gray J, Black H, Saunders E, Applegate W, Davidson J, Ginsberg D, Marbury T, Moser M, Cziner D, deSalva J, Mills D, Rosenblum J, Hall WD. Safety and efficacy of oncedaily captopril plus hydrochlorothiazide vs. nifedipine gastrointestinal therapeutic system in black patients with mild to moderate hypertension. American Journal of Therapeutics 1996; 3:811817. 31. Saunders, E., Goldsweig, HF.: Antihypertensive, Anti anginal, and Anti ischemic Effects of Mibefradil, AT Type Calcium Channel Antagonist, in Black Patients. J Natl Med Assn, May 1998. 32. Flack J.M., Yunis C., Preisser J., Holmes C.B., Mensah G., McLean B., Saunders E. The Rapidity of Drug Dose Escalation Influences Blood Pressure Response and Adverse Effects Burden in Patients with Hypertension: The Quinapril Titration Interval Management (ATIME) Study. ATIME Research Group. Arch. Intern. Med. 160:18421847, 2000. 33. Noel H.C., Saunders E., Smolensky M.H. Hypertension, Chronotherapy and Patient Management. Nurse Pract. 25:210, 2000. 34. Saunders E., Ferdinand K., Yellen L.G., Tonkon M.J., KrugGourley S., Poland M. Efficacy and Safety of Cerivastatin and Pravastatin in the Treatment of Primary Hypercholesterolemia. J. Natl. Med. Assoc. 92:319326, 2000. 35. Clark, L.T., Ferdinand, K.C., Flack, J.M., Gavin, James R., Hall, W.D., Kumanyika, S.K., Reed, J.W., Saunders, E., Valantine, H.A., Watson, K., Wenger, N.K., Wright, J.T. Coronary Heart Disease in African Americans. Heart Disease, Vol. 3, No.2, March, 2001. 36. Saunders, E., Gavin, JR., Blockade of the ReninAngiotensin System in African Americans With Hypertension and Cardiovascular Disease. Supplement Vol. V No. 1 January/February, 2003. The Journal of Clinical Hypertension. 37. Douglas J.D., Saunders, E., et. al. Management of High Blood Pressure in African Americans, Consensus Statement of Hypertension in African Americans Working Group of the Int. Svc. On Hypertension in Blacks. Arch Intern Med., Vol. 163. March 10, 2003. 38. Flack J, Oparil S, Pratt H, Roniker B, Garthwaite S, Kleiman J, Yang Y, Krause S, Workman D, Saunders E. Efficacy and Tolerability of Eplerenone and Losartan in Hypertensive Black and White Patients. Journal of the American College of Cardiology, Vol. 41, No. 7, April 2, 2003. 39. White W.B., Saunders, E., et. al. Comparative Efficacy and Safety of Nisoldipine Extended Release (ER) and Amlopidine (CESNAIII study) in African American Patients With Hypertension. American Journal of Hypertension, Vol. 16., No. 9. September 2003. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 21 of 25
40. Hall WD, Clark LT, Wenger NK, Wright JT, Kumanyika SK, Watson K, Horton EW, Flack JM, Ferdinand KC, Gavin JR, Reed JW, Saunders E, O’Neal W; AfricanAmerican Lipid and Cardiovascular Council. The Metabolic Syndrome in African Americans: a review. Ethn Dis Vol 4, 41428, 2003.
Refereed Publications (cont’d) Articles 41. Hall WD, Clark LT, Wenger NK, Wright JT, Kumanyika SK, Watson K, Horton EW, Flack JM, Ferdinand KC, Gavin JR, Reed JW, Saunders E, O’Neal W. For the patient. What is the Metabolic Syndrome and why is it important? Ethn Dis Vol. 13, 546, 2003. 42. White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of Nisoldipine extendedrelease (ER) and amlodipine (CESNAIII study) in African American patients with hypertension. American Journal of Hypertension Vol. 16, 73945, 2003. 43. Douglas JG, Bakins GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG, the Hypertension in African Americans Working Group. Management of High Blood Pressure in African Americans: Consensus Statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med, Vol. 163, March 10, 2003. 44. Mullins CD, Shaya FT, Flowers LR, Saunders E, Johnson W, Wong W. Health care cost of analgesic use in hypertensive patients. Clinical Therapy Vol. 26, 28593, February, 2004. 45. Mokwe E, Ohmit SE, Nasser SA, Shafi T, Saunders E, Crook E, Dudley A, Flack JM. Determinants of blood pressure in response to Quinapril in black and white hypertensive patients: the Quinapril Titration Interval Management Evaluation trial. Hypertension, Vol. 43: 12027, April, 2004. 46. Shaya, FT, Shin J, Mullins D, Fatodu H, Gu A, Saunders E. Medicaid Managed Care: Disparities in the Use of Thiazolidinediones Compared with Metformin. Journal of the National Medical Association, Vol. 97, No. 4, April, 2005. 47. Smith SC, Clark LT, Cooper RS, Daniels SR, Kumanyika SK, Ofili E, Quinones MA, Sanchez EJ, Saunders E, Tiukinhoy SD; American Heart Association Obesity, Metabolic Syndrome, and Hypertension Writing Group. Discovering the full spectrum of cardiovascular disease: Minority Health Summit 2003: report of the Obesity, Metabolic Syndrome, and Hypertension Writing Group. Circulation, Vol. 111, 1349, March, 2005. 48. Hertz RP., Saunders E. Racial Disparities in Hypertension Prevalence, Awareness and Management. Arch Inter Med, Vol. 165, Feb. 14, 2005. 49. Neutel JM., Saunders E., Bakris GL., Cushman WC, Ferdinand KC, Ofili EO, Sowers JR, Webb MA, INCLUSIVE Investigators. The Efficacy and Safety of Lowand HighDose Fixed Combinations of Irbesartan/Hydrochlorothiazide in Patients with Uncontrolled Systolic Blood Pressure on Monotherapy: The INCLUSIVE Trial. The Journal of Clinical Hypertension, Vol. 7, No. 10, October, 2005. 50. Saunders E, Smith WB, DeSalvo KB, Sullivan WA. The Efficacy and Tolerability of Nebivolol in Hypertensive African American Patients. The Journal of Clinical Hypertension, Vol. 9, No. 11, November 2007. 51. Flack JM, Victor R, Watson K, Ferdinand KC, Saunders E, Tarasenko L, Jamieson MJ, Shi H, Bruschi P. Improved Attainment of Blood Pressure and Cholesterol Goals Using SinglePill Amlodipine/Atorvastatin in African Americans: The CAPABLE Trial. Mayo Clinic Proceedings, Vol. 83, No. 1, 3545, January 2008. 52. Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, Sowers JR, Weber MA. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 22 of 25
Efficacy and Safety of Fixed Combinations of Irbesartan/Hydrochlorothiazide in Older Versus Younger Patients with Hypertension Uncontrolled on Monotherapy: The American Journal of Geriatric Cardiology, Vol. 17, February 2008 53. Saunders E, Ofili E. Epidemiology of Atherothrombotic Disease and the Effectiveness and Risks of Antiplatelet Therapy: Race and Ethnicity Considerations. Cardiology in Review, Vol. 16, No. 2, March/April 2008
Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 23 of 25
Non-Refereed Publications Articles 1.
Attar S, Saunders E. Prosthetic replacement of heart valves. Maryland State Medical Journal 1967; 16:109111.
2.
Saunders E. Dietary salt (sodium chloride) intake and arterial hypertension. Maryland State Medical Journal 1970 (August); 19(8):103104.
3.
Saunders E. Screening for hypertension. Maryland State Medical Journal 1973 (May); 22(5):3234.
4.
Saunders E. Adolescent hypertension. Urban Health Journal of Health Care in the Cities 1975 (Feb); 329 339. Saunders E. Cardiovascular diseases in nonwestern societies. Phylon 1977; 329339.
5. 6.
Saunders E, Kong BW. Sexual activity in male hypertensive patients while taking clonidine. Urban Health Journal of Health Care in the Cities 1980 (October); 2226.
7.
Saunders E, Kong BW, Jenkins P. The black hypertensive. Hypertension Clinics 1980; 1:15.
8.
Fitz AE, Saunders E. Longterm treatment of hypertension with methyldopa a retrospective multiclinic study, Therapeutic Efficacy. Journal of Cardiovascular Pharmacology 1981; 3:(chapter II) S8591.
9.
Saunders E, Kong BW. Hypertension and sex. Medical Aspects of Sexuality 1980; 14:118119.
10.
Saunders E. Implications and findings in the hypertension detection and followup program. Urban Health Journal 1981 (May); 2640.
11.
Kaplan NM, PerezStable E, Thompson GE, Saunders E. Minorities and high blood pressure. Dialogues on Hypertension 1982; 4:18.
12.
Kong BW, Saunders E. The church as a health resource. The Maryland Project. Hypertension Control in the Community, International Symposium (Tel Aviv, Israel) 1982 (November); 355337.
13.
Saunders E, Kong BW. A role for churches in hypertension management. Urban Health Journal 1983 (May); 4955.
14.
Saunders E, Kong BW. Precoital therapy for hypertensives. Medical Aspects of Human Sexuality 1984 (Jan); 247255.
15.
Southard JW, Entwisle G, Shankar B, Saunders E. Current status of hypertension in Maryland. Maryland State Medical Journal 1984 (March); 33(3):172173.
16.
Saunders E. Report of an NHLBI working conference on coronary heart disease in black populations. American Heart Journal 1984 (Sept); Vol. 108, No. 3, part 2:633634.
17.
Saunders E. High Blood Pressure and You. Prepared by the Maryland High Blood Pressure Coordination Council in Cooperation with the American Heart Association, Maryland Affiliate, Inc., 1979. Revised 1985.
18.
Saunders E. Black patients found to respond best to Ca++ entry blockers, diuretics. Current Controversies in Cardiovascular Medicine 1987; 3.
19.
Saunders E. Hypertension more frequent, severe in blacks. Symposium highlights. Update Cardiovascular Medicine 1987;1,8.
20.
Saunders E. Incidence and special challenges of hypertension in blacks. Journal of the National Medical Association 1987 (March); 79 Supplement:58. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 24 of 25
21.
Saunders E. Practical strategies for patient care and the role of the guandrel. Hypertension Highlights 1988; Vol. 9, No. 1.
Non-Refereed Publications (cont’d) Articles 22.
Saunders E. Controlling hypertension in the black population. Cardiology Today 1988; 35.
23.
Weir MR, Kritchen C, Urick A, Saunders E, Lavin PT. Comparison of enalapril and hydrochlorothiazide in mild hypertension and changes in plasma lipid concentrations during therapy. Clinical Therapeutics 1988; 10(6):712724.
24.
Hollenberg NK, Schoenberger JA, Dunn MI, Winer N, Saunders E. Questions from the audience. Modern Medicine 1988; Vol. 56, Suppl A:3739.
25.
Saunders E. Controlling hypertension in the black population. Inner City Physicians 1988 (March/April).
26.
Saunders E. Diuretics play an important role in select patient populations. Symposium Highlights. Modern Medicine 1988 (Jan); 2324.
27.
Saunders E. Use of Diuretics in special populations. Modern Medicine, Special Symposium Supplement 1988 (April); Vol. 56, Supplement A:3135.
28.
Saunders E. From the medical advisor. Black Health 1988; Premiere Issue.
29.
Davidson P, Saunders E. Profiled care approach to management of hypertension in blacks. Practical Cardiology 1988; Vol. 14, No. 5:91103.
30.
Weir MR, Saunders E. Pharmacologic management of systemic hypertension in blacks. American Journal of Cardiology 1988; Vol. 61:6H52H.
31.
Kaplan NM, Flamebaum WF, Izzo Jr JL, Kuller LH, Lowenthal DT, Saunders E, Weber MA, White WB. A roundtable discussion: therapeutic choices in volumedependant hypertension. Internal Medicine for the Specialist 1988 (Dec); Special Edition.
32.
Saunders E. Overview on papers presented at the second international interdisciplinary conference on hypertension in blacks. Clinical Cardiology 1989 (Dec); 12 (12 Suppl 4):IV 12.
33.
Saunders E, Estes NAM, Sheehan JP, Vertes V, Weir MR, Wright Jr JT. Physiologic approaches to blood pressure control and treatment of magnesium deficiency. Clinical Courier 1989; Vol. 7:18.
34.
Saunders E. Overview on papers presented at the second international interdisciplinary conference on hypertension in blacks. Clinical Cardiology 1989; 12(Suppl IV):12.
35.
Saunders E. Epidemiologic factors in the management of hypertension. Journal of the National Medical Association 1989; 81 (Suppl):511.
36.
Saunders E. Overview of hypertension among black patients. Epidemiology, pathophysiology and treatment. Procommunications 1989; 36.
37.
Saunders E. Introduction paper: cellular mechanisms in hypertension and therapeutic implications in blacks. Cardiovascular Drugs and Therapy 1990; Vol. 4:317319.
38.
Saunders E. Tailoring treatment to minority patients. American Journal of Medicine 1990; Vol. 88 (Suppl 3B):3B21S.
39.
Saunders E. Age and Race: implications for antihypertensive therapy. Practical Cardiology 1990 (Oct); Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 25 of 25
1822. 40.
Woodward TE, Saunders E, Kushner HA. Clinical care, education and research at the University of Maryland School of Medicine 18071991. Maryland Medical Journal 1991; 173179.
Non-Refereed Publications (cont’d) Articles 41.
Saunders E. Hypertension in African Americans. American Heart Association Medical/Scientific Statement 1991; Special Report Vol. 83, No. 4:14651467.
42.
Saunders E. Editorial overview: a special issue on hypertension. Journal Association for Academic Minority Physicians (JAAMP) 1991; Vol. 2, No. 4:142.
43.
Saunders E. Hypertension in the Black Population: Measures for Improving the Outlook. Cardiovascular Reviews & Reports, Vol. 13, No. 3, 1992
44. Francis CK, Oberman A, Saunders E. Racial and ethnic differences in CVD: managing risk factors. Patient Care, the Practical journal for Primary Care Physicians 1994. 45.
Saunders E. Therapeutic Implications. Medical Roundtable 1997 (Nov.8); 15.
46.
Saunders E. Commentary on “Comparing Conventional with Ambulatory Blood Pressure Measurement for Hypertension Management”, Cardiology Review, Nov. 1998, 15: 57.
47.
Saunders E. Benefits of Calcium Channel Antagonists in Controlling Hypertension in African American Patients: Factors in Drug Selection. The ABC Digest of Urban Cardiology, 6:1, 1115, January February 1999.
48.
Saunders E. Commentary on “Hypertension”, Cardiology Review, April 1999, 14:4.
49.
Saunders E. Commentary on “Hypertension”, “Applying Treatment guidelines to Patient Care”, Cardiology Review, September 2001, 18:10
50.
Saunders E. Clinical Therapeutics “Antihypertensive Efficacy and Safety of Losartan Alone and in Combination with Hydrochlorothiazide in Adult African Americans with Mild To Moderate Hypertension”, August 2001 23:8.
51.
Saunders E, Johnson, W. Management of HighRisk Hypertension Patients. Cardiology Special Edition, Vol. 8, No.2 of 2, 2002.
52.
Saunders E, Gavin JR, III. Blockade of the ReninAngiotensin System in African Americans With Hypertension and Cardiovascular Disease. The Journal of Clinical Hypertension: Supplement 1, Vol. V, No. 1, Jan/Feb., 2003
53.
Saunders E. Managing Hypertension in the African American Patient. The Journal of Clinical Hypertension: Supplement 1, Vol. VI, April, 2004.
54.
Saunders E. Hypertension in the HighRisk Patient: Focus on African Americans. Cardiology Special Edition Vol. 10, 2004.
55.
Saunders E. BP Control Essential for Diabetics. Renal & Urology News. Editor, Charnow, JA. August , 2005.
56.
Stewart D, Johnson W, Saunders E. Hypertension in Black Americans as a Special Population: Why So Special? Current Cardiology Reports, Vol. 8, No. 6, November 2006.
57.
Saunders E. Racial Disparities in Hypertension. Cardiology Quarterly, First Quarter 2007. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 26 of 25
Abstracts Numerous abstracts have been submitted for presentations at the following meetings annually: • American College of Cardiology • American Heart Association • International Society on Hypertension in Blacks • Association of Black Cardiologists • National Medical Association • American Society of Hypertension • Consortium for Southeastern Hypertension Control
Foreword 1.
Saunders E, Dixon BM, Wilson J. Foreword. In: Good Health for African Americans. Crown Publishers, Inc., New York, 1994.
2.
Saunders E. Foreword. In: Hodges GF, Belton HB. Spirituality and Medicine. Bloomington, IN, AuthorHouse, 2009
Pamphlets 1.
Saunders E. What Is High Blood Pressure? Facts You Should Know. The Wellness Report, published by Consolidated Health Services, Inc., Washington, DC, Volume No. 1, February 1993.
2.
Saunders E. Letter from the Editor. The Wellness Report, published by the Alliance Health Benefit Plan, Washington, DC, Volume No. 2, August, 1994.
3.
Saunders E. Letter from the Editor. The Wellness Report, published by the Alliance Health Benefit Plan, Washington, DC, Volume No. 4, Spring, 1995.
4.
Saunders E. High Blood Pressure. Body and Soul Health Guide, An AfricanAmerican's Guide to Healthy Living. For V103, page 32, 1994.
5.
Saunders E. High blood pressure. Body and Soul Health Guide, An AfricanAmerican's Guide to Healthy Living, for V103, update, 1995.
6.
Saunders E. Coping with Hypertension, Prolonging Healthy Lives, 1999
7.
Saunders E. What This Doctor Can Tell You About Hypertension Can Save Your Life. 2002
Newspapers 1.
Saunders E. TO YOUR HEALTH, BIweekly contribution to the Baltimore Sun Papers. HIGH BLOOD PRESSURE: SILENT, DEADLY, October 13, 1987.
2.
Saunders E. TO YOUR HEALTH, Surgery vs. drug treatment for heart disease, Baltimore Sun, November 5, 1987.
3.
Saunders E. TO YOUR HEALTH, Angioplasty: A popular alternative to bypass surgery, Baltimore Sun, November 24, 1987.
4.
Saunders E. TO YOUR HEALTH, Bypass not always appropriate medication sometimes best treatment for blocked arteries, Baltimore Sun, November 10, 1987.
5.
Saunders E. STATEN ISLAND SUNDAY ADVANCE, Hypertension, a slow silent killer among blacks, November 15, 1987 Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 27 of 25
6.
Saunders E. TO YOUR HEALTH, Dispelling myths, whispers about heart murmur, Baltimore Sun, December 8, 1987.
Newspapers (cont’d) 7.
Saunders E. ENTERPRISE, Coronary Angioplasty is now almost routine, Brockton, MA, December 17, 1987.
8.
Saunders E. TO YOUR HEALTH, Aspirin is gaining as drug for treating heart disease, Baltimore Sun, January 5, 1988.
9.
Saunders E. TO YOUR HEALTH, Mitral valve prolapse rarely needs treatment, March 8, 1988.
10.
Saunders E. TO YOUR HEALTH, Chest pain may simply be stress, March 22, 1988.
11.
Saunders E. TO YOUR HEALTH, Diet, drugs are weapons in battle against cholesterol, April 5, 1988.
12.
Saunders E. TO YOUR HEALTH, Calming heart flutters, majority of episodes are not diseaserelated, May 31, 1988.
13.
Saunders E. TO YOUR HEALTH, Chest pain is it a heart attack or something else, June 21, 1988.
14.
Saunders E. The Silent Killer, Black Church Magazine, March, 1988.
15.
Saunders E. Battling hypertension among blacks, Health News, Washington Post, March 15, 1988. (HealthPitch)
16.
Saunders E. Heart disease: How to beat the No. l killer of blacks, Ebony, 1988;148153.
17.
Saunders E. Hypertension screenings set for blacks, USA TODAY, 1988.
18. Saunders E. Recent report suggesting high blood pressure drug may cause heart attacks. Letter to the Editor, Sun Papers, 1995. 19. Saunders E. Interview with Jonathan Bov, Baltimore Sun Paper staff, “Better Care for Hypertension Urged,” March 10, 2003. 20. Baltimore Sun December 4, 2005: Taking Hypertension Fight Into the Church (Article features church blood pressure program and new barbershop/beauty salon programs initiative by Dr. Saunders’ team.
Films/Audiovisual Productions 1.
"Stroke Rehabilitation", American Heart Association, 1979.
2.
"High Blood Pressure Compliance", supported by Boehringer Ingelheim, Ltd. (Narrator: E.G. Marshall), 1980.
3.
"Early Warning Signs of Heart Attack", Spectrum, 1981.
4.
"Heart Attack Symptoms", American Heart Association and Maryland Institute for Emergency Medical Services
5.
"Hypertension: Number One Killer in the Black Community", narrated by James Earl Jones, produced by Urban Cardiology Research Center, featuring Elijah Saunders et al, shown nationally on LIFETIME CABLETELEVISION, aired November 22, November 29, December 6 and December 13, 1987. Beginning January 1, 1988, copies of the tape (either VHS or Beta) will be available on loan free from Urban Cardiology Research Center. Cost of this project and associated expenses were paid with an educational grant from Schering/Key Pharmaceuticals. (Video cassette) Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 28 of 25
6.
Chris Gaul, WBALTV, interviewed Dr. Patricia Davidson and Dr. Elijah Saunders, Hypertension Center, March l6, 1988.
7.
Guest appearance on show, Urban Scene, WBALTV Channel 11, discussing the topic "Blacks and Hypertension, March 29, 1988.
Films/Audiovisual Productions (cont’d) 8.
Health Pitch launches nationwide attack on "Silent Killer" Black America's #l Health Threat, Doremus, Porter, Novelli, HealthPITCH VNR (Video cassette), March, 1988.
9.
"Issues Unlimited", videotape, discussion of hypertension in the black community, Health Pitch, February, 1988.
10.
"Hypertension: #1 Killer in America", Lifetime Medical Television, January 1988 (Video cassette)
11.
Media Practice Session, Drs. E Saunders, J. Sowers and M Weir, Medical Video Productions, Decatur, GA, April 21, 1988.
12.
"Blacks in Medicine.” WMARTV, Channel 2, Annual African American Festival (AFRAM), selected as one of the honorees for blacks in medicine.
13.
CoHost, Wellness Alert Radio Program, WWINAM, 1991.
14.
Filming video news release on high blood pressure in African Americans for National Medical Association, Boasberg Valentine Radford (BVR) Public Relations, San Antonio TX, August 8, 1993.
15.
Media tour. Birmingham, AL, January 26, 1994. Topic: The Athlete's Heart and competing with heart disease.
16.
Media tour. Kansas City. “The Athlete's Heart and competing with heart disease.”
17.
Filming video (patients as well), Empowering America to control the blood pressure, University of Maryland Faculty Practice Office, Baltimore, MD, Ketchum Publications, March 1994.
18.
Time Life Medical, patient education videotape on hypertension, 1995.
19.
Filming video: South African Doll Project. Channel 45 and Channel 13, Baltimore, MD, 1995.
20.
WMARTV Dr. Ann Marie’s Evening and Nightly News (several times in 19971998)
21.
Maryland Public TV 8/98
22. WEAA (Morgan State University) Radio, Baltimore, MD., Baltimore Alliance, 8/98 23. WOLB, The Larry Sanders Show, Radio, Baltimore, MD., Baltimore Alliance, 5/99 24.
Coalition for the Advancement of Cardiovascular Health (COACH) ClinicCase Curriculum™: 45year old female with highrisk diabetes – Medical Education, 12/01
25.
BottomLine/Health – published article “The Salt Solution: Six Steps to Cut Your Intake”, 1/02
26. University of Maryland Medical System (UMMS) “Medifacts” – Article Hospital newsletter, “High Blood Pressure: Tips to Stop the Silent Killer”, 2/02 27. Planète Cardio, interview with the first French interactive magazine dedicated to cardiology, March, 2002 28. Press Conference with Baltimore and Washington, DC, TV station and local press on new guidelines, March 10, Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 29 of 25
2003. 29. Saunders E., Video News Release, “First Guidelines on Black Hypertension.” Produced by: International Society on Hypertension in Blacks (ISHIB), March 10, 2003. 30.
WRCTV; Interview with Dr. Elijah Saunders about diagnosing and treating high blood pressure on February, 2004 “sweeps” series on “the five most important medical test that could save your life”.
Films/Audiovisual Productions (cont’d) 31. WMARTV(Baltimore), WUSATV(Washington),WJZTV (Baltimore) Local Newspapers and Internet: “Education to Improve Patient Control of Hypertension and Diabetes” – 2005. 32. WJZTV Ch 13 (Baltimore) Interview with Dr. Saunders about a study that found a connection between the use of overthecounter painkillers and an increased risk of hypertension in women, 2005 33. WJZTV Ch 13: Dr. Elijah Saunders was interviewed about a study that found a connection between the use of overthecounter painkillers and an increased risk of hypertension in women, 8/15/2006 34. HealthDayNews.com: Dr. Saunders was quoted about Nebivolol, which is under FDA review, saying that the beta blocker appears to work in AfricanAmericans more effectively than other beta blockers on the market, 7/18/06. The story also appeared on the Atlanta JournalConstitution’s Web site and more than 12 other Web sites, including: Forbes.com: 7/18/06. DrKoop.com: 7/18/06. myDNA.com: 7/18/06. 35. Baltimore Afro American: Dr. Elijah Saunders was quoted in a story about a program in several Baltimore City barber and beauty shops to provide onsite blood pressure screenings, 7/15/06. 36. Baltimore Sun: Dr. Elijah Saunders was quoted in a story about the Community Health Awareness and Monitoring Program (CHAMP), a program he heads that is affiliated with the University of Maryland Medical Center. The program trains members of 25 Baltimore churches to take blood pressure readings, 7/7/06. Dr. Saunders was quoted in a similar story in the Baltimore Examiner, 7/27/06. 37. Baltimore Examiner: Dr. Elijah Saunders was quoted in an article about the results of a study of a combined blood pressure and anticholesterol medication that successfully lowered hypertension and reduced cholesterol in AfricanAmericans, 7/27/06. 38. WJZTV Ch 13: In a series of reports about life expectancy in Baltimore, the station included a quote from Dr. Elijah Saunders about a program in several Baltimore City barber and beauty shops to provide onsite blood pressure screenings, 9/12/06, 9/16/06. 39. Clarion Ledger (Jackson, MS): Dr. Saunders was quoted in a news brief about Nebivolol, a high blood pressure drug that may work better than other beta blockers among AfricanAmericans, 10/18/06. 40. Baltimore Sun: Dr. Saunders was quoted in an article on his efforts to detect hypertension in AfricanAmericans by organizing churches as blood pressure monitoring center, 12/4/06 41. HealthDay News (Internet news service): Dr. Saunders was quoted in an article about new government research that suggests that AfricanAmericans – women in particular – are especially susceptible to a clogging of the arteries in the legs, 12/21/06. HealthDay sends its reports to approximately 40 newspapers and television stations in the top ten markets. Coverage included: • • •
forbes.com: 12/21/06. Yahoo.com: 12/21/06. Healthcentral.com: 12/21/06. Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 30 of 25
• •
Realthealthmag.com: 12/21/06. Healthscout.com: 12/21/06.
42. WBALTV Ch 11: Dr. Saunders was featured in a public service announcement about the kickoff of a program in several Baltimore City barber and beauty shops that provides onsite blood pressure screenings. WJZTV Ch 13 interviewed Dr. Saunders for a news story about the program, which started in June, 6/28/06. The story was reported by the Baltimore Examiner, 6/26/06, and the Baltimore Times, 6/20/06. 43. WJZTV Ch 13: Dr. Saunders was interviewed for a story about a pill that combines blood pressure and cholesterollowering medications, 6/14/06.
Films/Audiovisual Productions (cont’d) 44. Baltimore Sun: Dr. Myung Park and Dr. Elijah Saunders were quoted in a frontpage story about a report in the Journal of the American Medical Association regarding the narrowing of the longevity gap between whites and blacks in the U.S., 3/20/07. The story also ran in the: • •
Orlando SunSentinel: 3/20/07. Newsday: 3/20/07.
45. Baltimore Sun and Web site, 4/1/07: Dr. Saunders was quoted on the front page and a photo caption mentioned Dr. Christopher deFilippi in an article concerning a study that looked at the heartpumping ability of people of different races. A UMMC heart transplant patient was pictured with Camille Styles, RN. 46. Baltimore Afro American: Dr. Saunders was quoted in a story about a program in several Baltimore City barber and beauty shops to provide onsite blood pressure screening, 7/15/07. 47. Baltimore Sun: Dr. Saunders was quoted in a story about the Community Health Awareness and Monitoring Program (CHAMP), a program he heads that is affiliated with the University of Maryland School of Medicine. The program trains members of 25 Baltimore churches to take blood pressure reading, 7/7/07. Dr. Saunders was quoted in a similar story in the Baltimore Examiner, 7/27/07. 48. Baltimore Examiner: Dr. Saunders was quoted in an article about the results of a study of a combined blood pressure and anticholesterol medication that successfully lowered hypertension and reduced cholesterol in AfricanAmericans, 7/27/07. 49. WJZTV Ch 13: In a series of reports about life expectancy in Baltimore, the station included a quote from Dr. Saunders about a program in several Baltimore City barber and beauty shops to provide onsite blood pressure screenings, 9/12/07, 9/16/07. 50. WJZTV, 9/20/08: Dr. Mandeep Mehra and Dr. Elijah Saunders were quoted in a story about a free blood pressure screening event in the Patient Resource Center featuring Hall of Fame football coach Don Shula. The story was also covered by: • • • •
WBFFTV WTEM Radio (Washington) WNST Radio (Towson) UMTV (UM College Park’s cable news service)
51. RedOrbit.com, 11/1/08: Dr. Elijah Saunders was quoted in a story about his study of a therapy for African Americans suffering from stage III hypertension. The story was also published in: • Internal Medicine World Report, 11/1/08 • PR Newswire, 11/1/08 • Interest!ALERT, 11/1/08 • MSNMoneyCentral, 11/1/08 • Excite News, 11/1/08 • KRNVTV (NV), 11/1/08 Revised 6/09
Curriculum Vitae Elijah Saunders, M.D., F.A.C.C., F.A.C.P. Page 31 of 25
• • • • •
Houston Examiner, (TX), 11/1/08 Yahoo! Finance Canada Medical News Today (U.K.) Baltimore Times and Web site, 11/16/08: included a photo of Dr. Saunders TheScientist.com, 11/19/08: an editorial on the issues raised by racially targeted trials, Written in response to Dr. Saunders’ study
52. Albany Times Union (NY), 2/14/08: Dr. Elijah Saunders was quoted in an article about blood pressure. The quotes were picked up from a story on our umm.edu Web site and the article was linked to the Web site. The writer credited the site as being his favorite place for healthrelated information. 53. WJZTV and Web site, 3/18/08: Dr. Saunders and a hypertension patient were interviewed in a story on the recent FDA approval of two new hypertension drugs.
Films/Audiovisual Productions (cont’d) 54. CBS Evening News, 3/31/08: Dr. Saunders was featured in a story about a program that teaches barbers how to monitor the blood pressure of patron in the barbershop. Stories on this subject also appeared on 16 local CBS affiliates, including: • • • • •
KYTXTV (TX) KPIXTV (San Francisco, CA) KCTV (MO) WROCTV (Rochester, NY) WREGTV (TN)
55. Baltimore Sun and Web site, 8/12/09: Dr. Elijah Saunders was quoted in an article that described the work of a Baltimore city task force on ways to reduce salt in the diet. Additional media coverage included: Baltimore Examiner and Web site, 8/12/09 WYPRFM, 8/13/09: Saunders appeared live on the Dan Rodricks Show. Government Innovators Network News Online, 8/15/09 SpiritIndia.com, 8/28/09
Revised 6/09